Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences,. It was first approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin’s Lymphoma (NHL), however, has now been approved for a variety of conditions. On November 28, 2018, the US FDA approved Truxima, the first biosimilar to Rituxan. It is grouped under the following drug class(es): Antineoplastic agents, Biologics, Immunosuppressants and Monoclonal antibodies. Its therapeutic use is listed as anti-cancer agents, anti-inflammatories and antirheumatic agents. The directory classifies it as a commercial API with a biotechnology source/manufacturing origin. Other names for this substance include Mab Thera, Truximab and rituximabum. Its PubChem CID is 168009840.
Rituximab
| CAS No | 174722-31-7 |
|---|---|
| Molecular Formula | C222H230N14O23S2 |
| Molecular Weight | 3526.0 g/mol |
| Synonyms | N/A |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.
The listed CAS number is 174722-31-7.
The listed molecular formula is C222H230N14O23S2.
The listed molecular weight is 3526.0 g/mol.
N/A.
The source lists Mab Thera, Truximab and rituximabum.